Nanotechnology-Based Targeting of mTOR Signaling in Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, M.-S. | - |
dc.date.available | 2020-11-09T01:40:31Z | - |
dc.date.created | 2020-08-31 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 1176-9114 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78898 | - |
dc.description.abstract | Mammalian target of rapamycin (mTOR) is a master regulator of cell growth and metabolism, which is activated in response to intra- and extracellular signals, including nutrients, growth factors, and cellular energy levels. The frequent dysregulation of mTOR signaling in cancer makes it an attractive therapeutic target, and several types of mTOR inhibitors have been developed. Nanoparticle-based mTOR modulators are predicted to target various cancers and deliver as well as release drugs in a controlled manner, resulting in enhanced bioavailability and reduced side effects. This mini-review is focused on the molecular mechanism of nanoparticle-based mTOR modulator action as well as the current development of mTOR inhibitors using nanoparticles. Understanding the biological function of nanoparticle-based mTOR modulators will contribute to the development of efficient nano-therapeutics for the treatment of cancers. © 2020 Yoon. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.relation.isPartOf | International journal of nanomedicine | - |
dc.title | Nanotechnology-Based Targeting of mTOR Signaling in Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000577115600006 | - |
dc.identifier.doi | 10.2147/IJN.S254574 | - |
dc.identifier.bibliographicCitation | International journal of nanomedicine, v.15, pp.5767 - 5781 | - |
dc.identifier.scopusid | 2-s2.0-85089822214 | - |
dc.citation.endPage | 5781 | - |
dc.citation.startPage | 5767 | - |
dc.citation.title | International journal of nanomedicine | - |
dc.citation.volume | 15 | - |
dc.contributor.affiliatedAuthor | Yoon, M.-S. | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | mammalian target of rapamycin | - |
dc.subject.keywordAuthor | mTOR kinase inhibitor | - |
dc.subject.keywordAuthor | nanoparticles | - |
dc.subject.keywordAuthor | nanotechnology | - |
dc.subject.keywordAuthor | RapaLinks | - |
dc.subject.keywordAuthor | rapalogs | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.